KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Debt to Equity (2016 - 2026)

Gilead Sciences filings provide 17 years of Debt to Equity readings, the most recent being $1.1 for Q4 2025.

  • On a quarterly basis, Debt to Equity fell 20.22% to $1.1 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1, a 20.22% decrease, with the full-year FY2025 number at $1.1, down 20.22% from a year prior.
  • Debt to Equity hit $1.1 in Q4 2025 for Gilead Sciences, down from $1.16 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $1.59 in Q1 2021 to a low of $1.1 in Q4 2023.
  • Median Debt to Equity over the past 5 years was $1.27 (2021), compared with a mean of $1.28.
  • The widest YoY moves for Debt to Equity: up 46.41% in 2021, down 26.46% in 2021.
  • Gilead Sciences' Debt to Equity stood at $1.27 in 2021, then fell by 6.13% to $1.19 in 2022, then fell by 7.67% to $1.1 in 2023, then increased by 25.81% to $1.38 in 2024, then dropped by 20.22% to $1.1 in 2025.
  • The last three reported values for Debt to Equity were $1.1 (Q4 2025), $1.16 (Q3 2025), and $1.27 (Q2 2025) per Business Quant data.